Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy

DALLAS, May 10, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced oral and poster presentations and a company-sponsored symposium at the upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place in Washington, D.C. from May 16-19, 2022.

Oral Presentations

- *3: Vagus Nerve Delivery of AAV9 to Treat Autonomic Nervous System Dysfunction in Giant Axonal Neuropathy*
  Presenter – Rachel Bailey, UT Southwestern
  Date/Time – Monday, May 16th at 10:45 AM Eastern Time
  Location – Room 204

- *470: Vectorized Delivery of Tau Reduction Therapy as a Treatment Approach for Tauopathies*
  Presenter – Rachel Bailey, UT Southwestern
  Date/Time – Tuesday, May 17th at 4:15 PM Eastern Time
  Location – Rm 204

Poster Presentations

- *157: Preclinical Gene Therapy with AAV9/SLC6A1 in a Mouse Model of SLC6A1 Related Disorder*
  Presenter – Weirui Guo, UT Southwestern
  Date/Time – Monday, May 16th at 5:30 PM Eastern Time
  Location – Poster Board M-38, Hall D

- *179: shRNA-Mediated Gene Therapy for the Treatment of Prader-Willi Syndrome*
  Presenter – Violeta Zaric, UT Southwestern
  Date/Time – Monday, May 16th at 5:30 PM Eastern Time
  Location – Poster Board M-60, Hall D

- *640: Gene Therapy Treatment in Young SLC13A5 Deficient Mice*
  Presenter – Rachel Bailey, UT Southwestern
  Date/Time – Tuesday, May 17th at 5:30 PM Eastern Time
  Location – Poster Board Tu-145, Hall D

- *557: shRNA-Mediated Gene Therapy for the Treatment of Angelman Syndrome*
  Presenter – Hye Ri Kang, UT Southwestern
  Date/Time – Tuesday, May 17th at 5:30 PM Eastern Time
  Location – Poster Board Tu-62, Hall D

- *642: Safety and Biodistribution Assessment in Non-Human Primates (NHPs) of a miniMECP2 AAV9 Vector for Gene-Replacement Therapy of Rett Syndrome*
  Presenter – Dr. Suyash Prasad, Taysha Gene Therapies
  Date/Time – Tuesday, May 17th at 5:30 PM Eastern Time
  Location – Poster board Tu-147, Hall D

- *1037: Safety Assessment of High-Dose miniMECP2 AAV9 Gene-Replacement Therapy (TSHA-102) for Rett Syndrome in Rats*
  Presenter – Mary Newman, Taysha Gene Therapies
  Date/Time – Wednesday, May 18th at 5:30 PM Eastern Time

Location –Poster board W-163, Hall D

Taysha-Sponsored Symposium

- *Accepting the Challenge: Innovative Approaches and Translational Strategies in Gene Therapy Development*
  Presenters – Dr. Suyash Prasad, Taysha Gene Therapies, Dr. Steven Gray, UT Southwestern, and Dr. Kimberly Goodspeed, UT Southwestern
  Date/Time – Tuesday, May 17th at 12:00 PM Eastern Time

Additional details can be found at the ASGCT 25th Annual Meeting website.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team's proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients' lives. More information is available at www.tayshagtx.com.

Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
klee@tayshagtx.com

Media Contact:
Carolyn Hawley
Canale Communications
carolyn.hawley@canalecomm.com

Source: Taysha Gene Therapies, Inc.